BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
To focus on providing safer burn treatments for women and armed forces
35 million mosquito nets supplied to countries in sub-Saharan Africa through partners
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
Xi Experience centre is aimed at familiarizing and bringing awareness about robotic-assisted surgery among the surgical fraternity in the country
Subscribe To Our Newsletter & Stay Updated
